Navigation Links
Sangamo BioSciences Announces Presentation At Regen Med Investor Day
Date:4/11/2013

lparsons@alliancerm.org">lparsons@alliancerm.org. Please visit http://alliancerm.org/event/regen-med-investor-day for more information.

About SangamoSangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
2. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
3. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
4. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
5. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
6. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
7. Sangamo BioSciences Reports First Quarter 2012 Financial Results
8. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... of building materials using light, developed by researchers at ... that are often considered the realm of science fiction, ... Although cloaked starships won,t be a reality for quite ... constructing materials with building blocks a few billionths of ... way that light flies through them, and works on ...
(Date:7/28/2014)... According to a new market research report published ... Joint) Market (By Technology - Stem Cell Therapy, ... Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products ... Growth, Trends and Forecast, 2013 - 2019" the ... valued at USD 2.6 billion in 2012 and ...
(Date:7/28/2014)... , July 28, 2014 ... report  "Microbial Identification Market by Products (Consumables, Instruments, Services), ... Beverages), End User (Detection, Characterization) - Global ... Microbial Identification Market is estimated at $896.5 ... reach $1,194.1 Million by 2019, growing at ...
(Date:7/28/2014)... 28, 2014 Appistry, Inc. , ... bring the power of genomics to next-generation medicine, announced ... Pipeline Challenge . , Two Appistry staff will ... National Center for Genome Resources, and Mr. Neil Miller, ... of Kansas City. Rounding out the panel are Appistry’s ...
Breaking Biology Technology:Building 'invisible' materials with light 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2
... researchers have identified a gene that is specifically responsible ... lead to stem cell therapies to treat brain injuries ... Edwin Monuki, doctoral student Karla Hirokawa and their colleagues ... Developmental & Cell Biology found that a gene called ...
... Jan. 17 NEXCORE Technology,Inc, a world-class original ... the intellectual property rights for the,development of a ... new system provides significantly greater control over the,inflow/outflow ... on the system are held by Drs. Atul ...
... Program Under Development to Improve Outcomes of Coronary ... Grafting (CABG) and Cardiac Valve Surgeries, VANCOUVER, ... -,Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... that they have entered into an,exclusive licensing agreement ...
Cached Biology Technology:Discovery of 'creator' gene for cerebral cortex points to potential stem cell treatments 2NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System 2Angiotech and Symphony Medical Announce Licensing Agreement 2Angiotech and Symphony Medical Announce Licensing Agreement 3Angiotech and Symphony Medical Announce Licensing Agreement 4Angiotech and Symphony Medical Announce Licensing Agreement 5Angiotech and Symphony Medical Announce Licensing Agreement 6
(Date:7/28/2014)... suggest two ways to effectively address the problem that birth ... compared to women of a normal body mass index. , ... as the population has increased in weight, concern has grown ... have consistently found that obesity has a negative impact on ... how well the pill prevents pregnancy. , "Birth ...
(Date:7/28/2014)... (July 28, 2014) Rice University researchers are ... of varying flexibility that can be used as microscale ... proof that "bead-spring" polymers, introduced as theory in the ... as required and should be of interest to materials ... The work led by Rice chemical and biomolecular engineer ...
(Date:7/28/2014)... body,s natural virus killers to prevent and treat HIV ... strong inflammatory response these molecules can arouse as they ... by scientists at the Weizmann Institute and the National ... activity of these molecules interferons around the ... course of the disease. Their research appeared in ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Seeing is bead-lieving 2Interfering with interferon 2
... syndrome has focused on the DYRK1A gene. The superexpression ... to Mr Garikoitz Azkona. In his PhD thesis, ... role of DYRK1A , Mr Azkona argues that this ... that persons with Down,s syndrome have regarding visual-spatial memory. ...
... 2010 2009 estimates projected that in the United States ... and 14,600 women would die of the disease. Often ... and a relatively low 5-year survival rate of about 45%. ... in the March 2010 issue of the Journal of ...
... treatment for cancer might come from fish says a new ... the FASEB Journal ( http://www.fasebj.org ). In the ... or "DHA," and its derivatives in the body kill neuroblastoma ... a wide range of cancers, including neuroblastoma, medulloblastoma, colon, breast, ...
Cached Biology News:DYRK1A gene may be 1 of most influential factors in Down syndrome 2Dietary factors influence ovarian cancer survival rates 2
... adsorption and clarification reagent; Ideal for ... of antibodies, proteins, nucleic acids, & ... cross-reactivity, and improves downstream processing; Utilizes ... non-ionic adsorbent supplied as a suspension ...
AC input: 230 V...
... The lyophilization stabilizer is designed ... process and for long-term storage. ... toxic ingredients. It is a ... pH 7.2, and is superior to ...
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
Biology Products: